Effects of prenatal AZT+3TC treatment on open field behavior and responsiveness to scopolamine in adult mice.
Treatment of pregnant seropositive women and their neonates with the nucleoside analogs (reverse transcriptase inhibitors) zidovudine (AZT), lamivudine (3TC) and their combination has become a standard of care in industrialized countries to prevent transmission of the HIV-1 virus. Animal studies indicated limited but significant behavioral changes in AZT or 3TC-prenatally exposed offspring, whereas data on the potential neurobehavioral outcomes of AZT+3TC combination are still lacking. The aim of the present study was to assess in mice prenatally exposed to AZT+3TC the functional state of cholinergic muscarinic neuroregulation at adulthood. Pregnant CD-1 mice received per orem twice daily AZT+3TC (160 and 500 mg/kg, respectively) or vehicle solution (NaCl 0.9%) from gestational day (GD) 10 to delivery (GD 19). Locomotor activity, exploratory behavior and responsiveness to the muscarinic cholinergic blocker scopolamine (2 mg/kg) were analyzed at adulthood (PND 70) in offspring of both sexes in an open field test. Results indicated that prenatal AZT+3TC exposure does not influence responsiveness to the muscarinic cholinergic antagonist as measured by analysis of the drug's effects on locomotor and exploratory activity and different behavioral items. However, AZT+3TC-treated mice displayed higher frequency of rearing, and lower frequency and duration of self-grooming behavior, consistent with an effect on dopaminergic neurotransmission. However, this would need confirmatory experiments.
Calamandrei
G
G
Section of Comparative Psychology, Laboratory of Pathophysiology O.S., Istituto Superiore di Sanità, Viale Regina Elena 299, I-00161, Rome, Italy. gemma@iss.it
Venerosi
A
A
Valanzano
A
A
Alleva
E
E
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects* / Q000502:physiology; D005260:Female; D019259:Lamivudine / Q000494:pharmacology*; D008297:Male; D051379:Mice; D018727:Muscarinic Antagonists / Q000494:pharmacology*; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*; D012601:Scopolamine / Q000494:pharmacology*; D015215:Zidovudine / Q000494:pharmacology*
D018727:Muscarinic Antagonists; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D012601:Scopolamine